# ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

> **NCT02874651** · PHASE2 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 25 (actual)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02874651
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2018-11-29
- **Final completion:** 2020-08-27
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Unacceptable toxicity (nasopharynx necrosis and massive hemorrhage)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874651, "ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02874651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*